Nasus Pharma (NYSEAMERICAN:NSRX) CEO Dan Benjamin Teleman Purchases 6,550 Shares

Nasus Pharma Ltd. (NYSEAMERICAN:NSRX) CEO Dan Benjamin Teleman bought 6,550 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were purchased at an average cost of $3.10 per share, with a total value of $20,305.00. Following the transaction, the chief executive officer directly owned 163,541 shares of the company’s stock, valued at $506,977.10. The trade was a 4.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Dan Benjamin Teleman also recently made the following trade(s):

• On Wednesday, April 22nd, Dan Benjamin Teleman purchased 2,900 shares of Nasus Pharma stock. The shares were acquired at an average price of $3.76 per share, for a total transaction of $10,904.00.

Nasus Pharma Stock Performance

Shares of Nasus Pharma stock opened at $3.07 on Monday. The company’s 50 day moving average is $2.94. Nasus Pharma Ltd. has a 12-month low of $1.98 and a 12-month high of $9.99.

Analyst Ratings Changes

Separately, Citizens Jmp cut their price target on Nasus Pharma from $19.00 to $18.00 and set a “market outperform” rating for the company in a research note on Thursday, March 26th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Nasus Pharma presently has an average rating of “Buy” and a consensus price target of $18.00.

Nasus Pharma Company Profile

Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.